{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:25:18Z","timestamp":1792409118291,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006140.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000}}],"reference-count":97,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006140.pub3","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:31:27Z","timestamp":1746772287000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sustained-release naltrexone for opioid dependence"],"prefix":"10.1002","volume":"2025","author":[{"given":"Hege","family":"Korn\u00f8r","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Sports and Mental Health; Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Paul K","family":"Lobmaier","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research; University of Oslo; Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj","family":"Kun\u00f8e","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Addiction; Lovisenberg Diakonale Sykehus; Oslo Norway"},{"name":"Department for Public Health and Interdisciplinary Health Sciences; University of Oslo; Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"10.1002\/14651858.CD006140.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/add.13753","article-title":"Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot\/feasibility randomized trial","volume":"112","author":"Korthuis","year":"2017","journal-title":"Addiction"},{"issue":"7","key":"10.1002\/14651858.CD006140.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/add.15836","article-title":"HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial","volume":"117","author":"Korthuis","year":"2022","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0003|cit3","unstructured":"Comparing treatments for hiv-infected opioid users in an integrated care effectiveness study (CHOICES) scale-up https:\/\/clinicaltrials.gov\/show\/NCT03275350"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomised, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"108076","DOI":"10.1016\/j.jsat.2020.108076","article-title":"A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder","volume":"117","author":"Farabee","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0006|cit6","unstructured":"Injectable pharmacotherapy for opioid use disorders (IPOD) https:\/\/clinicaltrials.gov\/show\/NCT02110264"},{"issue":"10","key":"10.1002\/14651858.CD006140.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","article-title":"Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone","volume":"66","author":"Hulse","year":"2009","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.drugalcdep.2018.12.026","article-title":"The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: a randomized trial","volume":"197","author":"Jarvis","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"9776","key":"10.1002\/14651858.CD006140.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/add.14735","article-title":"Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism","volume":"115","author":"Nunes","year":"2019","journal-title":"Addiction"},{"issue":"9","key":"10.1002\/14651858.CD006140.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"Krupitsky","year":"2012","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Yaroslavtseva T Krupitsky E Zvartau E Blokhina E Woody G The impact of oral and implantable formulations of naltrexone on overall functioning and social adjustment in opioid dependent patients European Neuropsychopharmacology 2014 s689 90","DOI":"10.1016\/S0924-977X(14)71111-3"},{"issue":"4","key":"10.1002\/14651858.CD006140.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1016\/S2352-3018(18)30362-X","article-title":"Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial","volume":"6","author":"Krupitsky","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0014|cit14","unstructured":"Adherence to HIV therapy in heroin addicts: oral vs XR-NTX https:\/\/clinicaltrials.gov\/show\/NCT01101815"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1192\/bjp.bp.108.055319","article-title":"Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial","volume":"194","author":"Kun\u00f8e","year":"2009","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended release naltrexone: a pilot proof-of-concept randomized effectiveness trial","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0017|cit17","unstructured":"Extended-release naltrexone for opioid relapse prevention following release from jail https:\/\/clinicaltrials.gov\/show\/NCT01180647"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cct.2015.01.005","article-title":"Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial","volume":"41","author":"Lee","year":"2015","journal-title":"Contemporary Clinical Trials"},{"issue":"13","key":"10.1002\/14651858.CD006140.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006140.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/08897077.2020.1809603","article-title":"Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders","volume":"42","author":"Pivovarova","year":"2021","journal-title":"Substance Abuse"},{"issue":"3","key":"10.1002\/14651858.CD006140.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000313336","article-title":"Naltrexone implants compared to methadone: outcomes six months after prison release","volume":"16","author":"Lobmaier","year":"2010","journal-title":"European Addiction Research"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"108407","DOI":"10.1016\/j.jsat.2021.108407","article-title":"Extended-release naltrexone for youth with opioid use disorder","volume":"130","author":"Mitchell","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0023|cit23","unstructured":"Extended release naltrexone for opioid-dependent youth https:\/\/clinicaltrials.gov\/show\/NCT01843023"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0024|cit24","unstructured":"Naltrexone and behavioral drug and hiv risk reduction counseling in Russia https:\/\/clinicaltrials.gov\/show\/NCT01389167"},{"issue":"3","key":"10.1002\/14651858.CD006140.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3310\/hta23030","article-title":"Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT","volume":"23","author":"Strang","year":"2019","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cct.2014.09.002","article-title":"Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community","volume":"39","author":"Di Paola","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cct.2014.09.002","article-title":"Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community","volume":"39","author":"Di Paola","year":"2014","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0028|cit28","unstructured":"Naltrexone for opioid dependent released human immunodeficiency virus positive (HIV+) criminal justice populations https:\/\/clinicaltrials.gov\/show\/NCT01246401"},{"issue":"1","key":"10.1002\/14651858.CD006140.pub3-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial","volume":"78","author":"Springer S","year":"2018","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1176\/appi.ajp.2018.17070732","article-title":"A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder","volume":"176","author":"Sullivan","year":"2019","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/jamapsychiatry.2018.3537","article-title":"Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone","volume":"76","author":"Latif","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD006140.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0033|cit33","unstructured":"Tanum L Solli KK Use of benzodiazepines among opioid dependent individuals during a 12 week randomized study and a 36-week follow-up study with extended release naltrexone Heroin Addiction and Related Clinical Problems 2018 23"},{"issue":"5","key":"10.1002\/14651858.CD006140.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial","volume":"169","author":"Tiihonen","year":"2012","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA Clinical Trials Network CTN-0051, Extended-release naltrexone vs. buprenorphine for opioid treatment (X: BOT): study design and rationale","volume":"50","author":"Lee","year":"2016","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0037|cit37","unstructured":"Extended-release naltrexone vs. buprenorphine for opioid treatment https:\/\/ClinicalTrials.gov\/show\/NCT02032433"},{"issue":"9","key":"10.1002\/14651858.CD006140.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"S268","DOI":"10.1016\/j.biopsych.2020.02.694","article-title":"Depression and suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone","volume":"87","author":"Rizk","year":"2020","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cct.2016.05.002","article-title":"Extended-release naltrexone opioid treatment at jail reentry (XOR)","volume":"49","author":"McDonald","year":"2016","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0040|cit40","unstructured":"Extended-release naltrexone opioid treatment at jail re-entry (XOR) https:\/\/ClinicalTrials.gov\/show\/NCT01999946"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0041|cit41","unstructured":"An open-label, phase 3 study of the safety of the O\u2019Neil Long Acting Naltrexone Implant treatment for substance dependence https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=ACTRN12609000682246 2009"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jsat.2015.07.005","article-title":"A phase 4, pilot, open-label study of VIVITROL (extended-release naltrexone XR-NTX) for prisoners","volume":"59","author":"Gordon","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cct.2016.12.015","article-title":"Extended-release naltrexone for pre-release prisoners: a randomized trial of medical mobile treatment","volume":"53","author":"Gordon","year":"2017","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"S575","DOI":"10.1016\/S0924-977X%2813%2970916-7","article-title":"Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long acting sustained release naltrexone implant","volume":"23","author":"Krupitsky","year":"2013","journal-title":"European Neuropsychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD006140.pub3-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction (Abingdon, England)"},{"issue":"11","key":"10.1002\/14651858.CD006140.pub3-BIB0046|cit46","first-page":"49","article-title":"Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy","volume":"114","author":"Krupitsky","year":"2014","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova"},{"issue":"1","key":"10.1002\/14651858.CD006140.pub3-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13722-020-00188-5","article-title":"Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials","volume":"15","author":"Murphy","year":"2020","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0048|cit48","unstructured":"Employment-based depot naltrexone clinical trial II https:\/\/clinicaltrials.gov\/study\/NCT00684775 2008"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0049|cit49","unstructured":"Evaluating naltrexone for use in conjunction with buprenorphine in adults with opioid use disorder transitioning from buprenorphine maintenance prior to first dose of VIVITROL https:\/\/clinicaltrials.gov\/study\/NCT02696434 2016"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0050|cit50","unstructured":"Long-acting naltrexone for pre-release prisoners clinicaltrials.gov\/study\/NCT02867124"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0051|cit51","unstructured":"Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder clinicaltrials.gov\/study\/NCT05011266"},{"issue":"1-3","key":"10.1002\/14651858.CD006140.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2011.06.012","article-title":"Drug use and HIV risk outcomes in opioid-injecting men in the Republic of Georgia: behavioral treatment + naltrexone compared to usual care","volume":"120","author":"Otiashvili","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"108241","DOI":"10.1016\/j.jsat.2020.108241","article-title":"A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail","volume":"128","author":"Gordon","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0054|cit54","unstructured":"Extended release naltrexone versus extended release buprenorphine with individuals leaving jail clinicaltrials.gov\/study\/NCT04408313"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0055|cit55","unstructured":"Comparing efficacy of extended-release injectable naltrexone (XR-NTX) with oral naltrexone http:\/\/en.irct.ir\/trial\/45796"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0056|cit56","unstructured":"Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults clinicaltrials.gov\/study\/NCT04219540"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"108389","DOI":"10.1016\/j.jsat.2021.108389","article-title":"Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)","volume":"128","author":"Waddell","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1002\/14651858.CD006140.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/add.14946","article-title":"Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis","volume":"115","author":"Bahji","year":"2020","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0059|cit59","unstructured":"Opioid crisis: Fall in US overdose deaths leaves experts scrambling for an explanation https:\/\/www.bmj.com\/content\/386\/bmj.q2091.full 10.1136\/bmj.q2091"},{"issue":"1","key":"10.1002\/14651858.CD006140.pub3-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: The current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0061|cit61","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"9904","key":"10.1002\/14651858.CD006140.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(13)61530-5","article-title":"Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Degenhardt","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0063|cit63","volume-title":"SCL-90-R: Administration, Scoring and Procedures Manual","author":"Derogatis","year":"1994"},{"issue":"3","key":"10.1002\/14651858.CD006140.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","article-title":"Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone","volume":"30","author":"Dunbar","year":"2006","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"1","key":"10.1002\/14651858.CD006140.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/neurolint14010004","article-title":"Naltrexone Implant for Opioid Use Disorder","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurology International"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0066|cit66","volume-title":"Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition (SCID-I\/P)","author":"First","year":"2002"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0067|cit67","first-page":"56","article-title":"Measurement of quality of life: current state of the art","volume":"63","author":"Flanagan","year":"1982","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"7454","key":"10.1002\/14651858.CD006140.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"The GRADE working group","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0069|cit69","unstructured":"GRADEpro Guideline Development Tool McMaster University and Evidence Prime 2024"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0070|cit70","doi-asserted-by":"crossref","unstructured":"Handelsman L Cochrane KJ Aronson MJ Ness R Rubinstein KJ Kanof PD Subjective Opiate Withdrawal Scale (SOWS) [Database record] APA PsycTests 1987 10.1037\/t29399-000","DOI":"10.1037\/t29399-000"},{"issue":"343","key":"10.1002\/14651858.CD006140.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"18","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0072|cit72","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/HRP.0000000000000052","article-title":"Long-term course of opioid addiction","volume":"23","author":"Evans","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006140.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"8","key":"10.1002\/14651858.CD006140.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/sj.npp.1301572","article-title":"Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence","volume":"33","author":"Jayaram-Lindstr\u00f6m","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD006140.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/add.15087","article-title":"Global opioid agonist treatment: a review of clinical practices by country","volume":"115","author":"Jin","year":"2020","journal-title":"Addiction"},{"issue":"3","key":"10.1002\/14651858.CD006140.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/09595230500170241","article-title":"From opioid maintenance to abstinence: a literature review","volume":"24","author":"Korn\u00f8r","year":"2005","journal-title":"Drug and Alcohol Review"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Kun\u00f8e N Lobmaier P Blame the counselling, not the implant. A response to Oliver, Horspool & Keen (2005) Addiction 2005 100 7 1027 8 10.1111\/j.1360-0443.2005.01209.x","DOI":"10.1111\/j.1360-0443.2005.01209.x"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Kun\u00f8e N Lee JD Opioid addiction: long-acting formulations for a long-term disorder [comment] Lancet 2019 393 1073 723 4 10.1016\/S0140-6736(18)32428-0","DOI":"10.1016\/S0140-6736(18)32428-0"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/add.14847","article-title":"Commentary on Nunes et al. (2020): Blocked opioid use in antagonist treatment\u2014time for cognitive and user-centered perspectives","volume":"115","author":"Kun\u00f8e","year":"2020","journal-title":"Addiction"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1369-1600.2012.00462.x","article-title":"Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients: fMRI of depot-naltrexone","volume":"19","author":"Langleben","year":"2014","journal-title":"Addiction Biology"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/dar.12095","article-title":"A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence","volume":"33","author":"Larney","year":"2014","journal-title":"Drug and Alcohol Review"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Lee JD Kun\u00f8e N Extended-release opioid antagonists and HIV treatment [comment] Lancet HIV 2019 6 4 e206 7 10.1016\/S2352-3018(19)30040-2","DOI":"10.1016\/S2352-3018(19)30040-2"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neuroimage.2013.03.055","article-title":"Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study","volume":"78","author":"Lukas","year":"2013","journal-title":"NeuroImage"},{"issue":"4","key":"10.1002\/14651858.CD006140.pub3-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001333.pub4","article-title":"Oral naltrexone maintenance treatment for opioid dependence","author":"Minozzi","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD006140.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1111\/add.15153","article-title":"Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism","volume":"115","author":"Nunes","year":"2020","journal-title":"Addiction"},{"issue":"8","key":"10.1002\/14651858.CD006140.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","article-title":"A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients","volume":"28","author":"Oslin","year":"2003","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0088|cit88","unstructured":"Review Manager Web (RevMan Web) Cochrane 2023"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0089|cit89","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0090|cit90","volume-title":"EPPI-Reviewer 4: software for research synthesis. EPPI-Centre Software","author":"Thomas","year":"2018"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0091|cit91","volume-title":"World Drug Report 2024","year":"2024"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","article-title":"A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction","volume":"30","author":"Veilleux","year":"2010","journal-title":"Clinical Psychology Review"},{"issue":"1","key":"10.1002\/14651858.CD006140.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-med-011817-044739","article-title":"Use and misuse of opioids in chronic pain","volume":"69","author":"Volkow","year":"2018","journal-title":"Annual Review of Medicine"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0094|cit94","volume-title":"Theory of Addiction","author":"West","year":"2014"},{"key":"10.1002\/14651858.CD006140.pub3-BIB0095|cit95","volume-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009"},{"issue":"6","key":"10.1002\/14651858.CD006140.pub3-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD006140.pub3-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006140.pub2","article-title":"Sustained-release naltrexone for opioid dependence","author":"Lobmaier","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:04:44Z","timestamp":1770372284000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006140.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":97,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006140.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}